Triptan efficacy in migraine attacks

From appropriate diagnosis to metabolic profiles and pharmacogenomics

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A major, revolutionary advance in acute migraine therapy was the development of sumatriptan, a selective 5-HT1B/1D receptor agonist. After sumatriptan, the so-called second generation-triptans have become available and at present 7 triptans are on the market. Activation of the trigeminal nerve is a key component of the cascade that leads to, and perpetuates, a migraine attack. Sumatriptan and the other triptans currently on the market (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) are potent agonists of the 5-HT1B and 5-HT1D receptors, and some are potent 5-HT1F agonists. The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success. Further possibilities are offered by studying metabolic profiles of molecules in order to tailor the best treatment option for each patient, and obtain the best efficacy profiles and the lower rate of drug-adverse events.

Original languageEnglish
Pages (from-to)335-340
Number of pages6
JournalDrug Development Research
Volume68
Issue number6
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Tryptamines
Sumatriptan
Metabolome
Pharmacogenetics
Migraine Disorders
zolmitriptan
Receptor, Serotonin, 5-HT1D
Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT1B
Pharmaceutical Preparations
Trigeminal Nerve
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Chemical activation
Molecules

Keywords

  • Metabolism
  • Migraine
  • Pharmacogenomics
  • Triptans

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

@article{7ce4c3fb47934cfe91e3fceb7dae1789,
title = "Triptan efficacy in migraine attacks: From appropriate diagnosis to metabolic profiles and pharmacogenomics",
abstract = "A major, revolutionary advance in acute migraine therapy was the development of sumatriptan, a selective 5-HT1B/1D receptor agonist. After sumatriptan, the so-called second generation-triptans have become available and at present 7 triptans are on the market. Activation of the trigeminal nerve is a key component of the cascade that leads to, and perpetuates, a migraine attack. Sumatriptan and the other triptans currently on the market (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) are potent agonists of the 5-HT1B and 5-HT1D receptors, and some are potent 5-HT1F agonists. The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success. Further possibilities are offered by studying metabolic profiles of molecules in order to tailor the best treatment option for each patient, and obtain the best efficacy profiles and the lower rate of drug-adverse events.",
keywords = "Metabolism, Migraine, Pharmacogenomics, Triptans",
author = "Buzzi, {M. Gabriella}",
year = "2007",
month = "9",
doi = "10.1002/ddr.20197",
language = "English",
volume = "68",
pages = "335--340",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Triptan efficacy in migraine attacks

T2 - From appropriate diagnosis to metabolic profiles and pharmacogenomics

AU - Buzzi, M. Gabriella

PY - 2007/9

Y1 - 2007/9

N2 - A major, revolutionary advance in acute migraine therapy was the development of sumatriptan, a selective 5-HT1B/1D receptor agonist. After sumatriptan, the so-called second generation-triptans have become available and at present 7 triptans are on the market. Activation of the trigeminal nerve is a key component of the cascade that leads to, and perpetuates, a migraine attack. Sumatriptan and the other triptans currently on the market (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) are potent agonists of the 5-HT1B and 5-HT1D receptors, and some are potent 5-HT1F agonists. The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success. Further possibilities are offered by studying metabolic profiles of molecules in order to tailor the best treatment option for each patient, and obtain the best efficacy profiles and the lower rate of drug-adverse events.

AB - A major, revolutionary advance in acute migraine therapy was the development of sumatriptan, a selective 5-HT1B/1D receptor agonist. After sumatriptan, the so-called second generation-triptans have become available and at present 7 triptans are on the market. Activation of the trigeminal nerve is a key component of the cascade that leads to, and perpetuates, a migraine attack. Sumatriptan and the other triptans currently on the market (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) are potent agonists of the 5-HT1B and 5-HT1D receptors, and some are potent 5-HT1F agonists. The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success. Further possibilities are offered by studying metabolic profiles of molecules in order to tailor the best treatment option for each patient, and obtain the best efficacy profiles and the lower rate of drug-adverse events.

KW - Metabolism

KW - Migraine

KW - Pharmacogenomics

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=38149061072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149061072&partnerID=8YFLogxK

U2 - 10.1002/ddr.20197

DO - 10.1002/ddr.20197

M3 - Article

VL - 68

SP - 335

EP - 340

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 6

ER -